Literature DB >> 20400894

Thrombophilic factors in idiopathic intracranial hypertension: a report of 51 patients and a meta-analysis.

Anat Kesler1, Efrat Kliper, Einor Ben Assayag, Eti Zwang, Varda Deutsch, Uriel Martinowitz, Aharon Lubetsky, Shlomo Berliner.   

Abstract

Several studies have suggested that thrombophilic risk factors are more prevalent in individuals with idiopathic intracranial hypertension (IIH), and that a prothrombic state may be involved in the etiopathogenesis of this disease. We examine thrombophilic factors in a group of patients with IIH in relation to obesity. In addition, we reviewed the relevant literature and performed a meta-analysis. Thrombophilia work-up was performed on 51 patients with IIH at least 1 month following their first episode. Samples for the analysis of factor V Leiden (FVL), prothrombin gene variant (PGV) G20210A and methylenetetrahydrofolate reductase (MTHFR) were available in an additional 30 patients, that is 81 patients in all. Meta-analysis was performed. Of the 51 patients 40 were obese. Increased concentrations of fibrinogen, D-Dimer, factor VIII, factor IX and factor XI were found in 15, 7, 7, 6 and 2 patients, respectively, all obese. The circulating anticoagulant, measured by dilute Russell's viper venom time (dRVVT assay), found mainly in obese. All 51 patients were negative for the anticardiolipin antibody (IgG immunoglobulin G) and IgG anti-beta2 glycoprotein I. In the meta-analysis antiphospholipid antibodies were significantly associated with IIH [odds ratio (OR) of 4.25 (1.68-12.60)], similar to the association with high factor VIII [OR = 16.17 (2.87-91.01)], higher plasminogen activator inhibitor-1 (PAI-1) levels [OR = 6.91 (2.28-20.91)], and high lipoprotein (a) [LP(a)] [OR = 3.54 (1.54-8.70)]. Obesity often observed in IIH patients is frequently linked with thrombophilic factors. Thus, we believe that dysmetabolism could be the thrombophilic target for treatment in patients with IIH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20400894     DOI: 10.1097/MBC.0b013e328338ce12

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  9 in total

Review 1.  [Idiopathic intracranial hypertension].

Authors:  J Bäuerle; K Egger; A Harloff
Journal:  Nervenarzt       Date:  2017-02       Impact factor: 1.214

2.  Increased levels of interleukins 2 and 17 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension.

Authors:  Laura J Edwards; Basil Sharrack; Azza Ismail; Christopher R Tench; Bruno Gran; Samish Dhungana; Johannes Brettschneider; Hayrettin Tumani; Cris S Constantinescu
Journal:  Am J Clin Exp Immunol       Date:  2013-10-16

Review 3.  Update on the pathophysiology and management of idiopathic intracranial hypertension.

Authors:  Valérie Biousse; Beau B Bruce; Nancy J Newman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-03-15       Impact factor: 10.154

4.  [Intracranial hypertension and jugular vein thrombosis].

Authors:  J Konrad; R Vogt; H Helbig; I Oberacher-Velten
Journal:  Ophthalmologe       Date:  2015-12       Impact factor: 1.059

Review 5.  [Sinus thrombosis and idiopathic intracerebral hypertension: Thrombophilia and hormonal influence as potentially relevant causal connections].

Authors:  Rainer B Zotz
Journal:  Ophthalmologe       Date:  2015-10       Impact factor: 1.059

6.  Update on idiopathic intracranial hypertension.

Authors:  Beau B Bruce; Valérie Biousse; Nancy J Newman
Journal:  Am J Ophthalmol       Date:  2011-06-21       Impact factor: 5.258

7.  The laboratory profile in idiopathic intracranial hypertension.

Authors:  Lea Pollak; Efrat Zohar; Yoseph Glovinsky; Ruth Huna-Baron
Journal:  Neurol Sci       Date:  2015-01-18       Impact factor: 3.307

8.  Personalized medicine in human space flight: using Omics based analyses to develop individualized countermeasures that enhance astronaut safety and performance.

Authors:  Michael A Schmidt; Thomas J Goodwin
Journal:  Metabolomics       Date:  2013-06-27       Impact factor: 4.290

Review 9.  Idiopathic intracranial hypertension, hormones, and 11β-hydroxysteroid dehydrogenases.

Authors:  Keira A Markey; Maria Uldall; Hannah Botfield; Liam D Cato; Mohammed A L Miah; Ghaniah Hassan-Smith; Rigmor H Jensen; Ana M Gonzalez; Alexandra J Sinclair
Journal:  J Pain Res       Date:  2016-04-19       Impact factor: 3.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.